4.11
4.11 (0%)
As of Apr 25, 2025
Phathom Pharmaceuticals, Inc. [PHAT]
Source:
Company Overview
Phathom Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA , VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK , contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of medicines that block acid secretion in the stomach.
| Country | United States |
| Headquarters | florham park, new jersey |
| Phone Number | (877) 742-8466 |
| Industry | manufacturing |
| CEO | Terrie Curran |
| Website | www.phathompharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $55.3 |
| Operating Profit | $-277.5 |
| Net Income | $-334.3 |
| Net Cash | $-84.1 |
Profit Ratios
| Gross Margin | $47.3 |
| Operating Margin | -502.2 |
| Profit as % of Revenues | -14.1% |
| Profit as % of Assets | -84.4% |
| Profit as % of Stockholder Equity | 131.8% |
Management Effectiveness
| Return on Equity | 131.8% |
| Return on Assets | -88.4% |
| Turnover Ratio | 14% |
| EBITA | $-277.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $378.3 |
| Total Liabilities | $631.9 |
| Operating Cash Flow | $-266.8 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $182.8 |
